Loading...
XASE
RVP
Market cap20mUSD
Jul 09, Last price  
0.70USD
1D
-0.57%
1Q
3.98%
Jan 2017
-25.08%
IPO
-93.20%
Name

Retractable Technologies Inc

Chart & Performance

D1W1MN
XASE:RVP chart
P/E
P/S
0.55
EPS
Div Yield, %
Shrs. gr., 5y
-2.11%
Rev. gr., 5y
-14.11%
Revenues
38m
+15.78%
25,324,51926,289,72027,899,31838,981,83736,219,56232,102,29633,644,50330,785,12734,520,63029,552,20029,826,63634,493,83833,274,70241,797,17981,862,453188,382,45494,818,93843,596,92633,049,53338,266,211
Net income
-13m
L+5.71%
-3,869,484-6,948,104-9,643,580-9,422,3002,400,6941,418,482-4,132,892-6,213,852-2,354,6054,314,318-3,694,907-3,736,038-1,339,9433,148,23424,223,01356,064,2415,078,557-7,011,036-11,886,524-12,565,230
CFO
-7m
L-38.87%
-3,354,031-4,216,671-5,923,242-12,299,7318,730,6725,513,773158,3372,933,569-3,867,822-3,252,157-794,912-2,922,636-1,195,4952,194,63818,997,02932,793,49816,768,1282,766,848-11,557,036-7,064,378

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Retractable Technologies, Inc. is a medical device company focused on the innovation, production, and sale of secure medical instruments, predominantly syringes, for the healthcare sector. Their reach extends across the United States, the broader North and South American continents, and other international territories. The company's diverse product range includes a variety of safety-engineered items such as VanishPoint insulin, tuberculin, and allergy antigen syringes, as well as Patient Safe syringes and Luer Caps. They also offer small diameter tube adapters, blood collection tube holders, allergy trays, and IV safety catheters. Further offerings feature VanishPoint blood collection sets, EasyPoint needles, and VanishPoint autodisable syringes. Distribution of these products occurs through a combination of general and specialized distributors, international partners, and a dedicated direct sales network. Founded in 1994, the company's main operations are headquartered in Little Elm, Texas.
IPO date
May 04, 2001
Employees
190
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT